NCT04787848View on ClinicalTrials.gov

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

December 30, 2025

Conditions
Chronic Widespread Pain
Interventions
DRUG

Relistor Injectable Product

Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation

Trial Locations (1)

33199

RECRUITING

Ambulatory Care Center, Florida International University, Miami

All Listed Sponsors
lead

Florida International University

OTHER